…
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -26.20M | -34.60M | -49.39M | -29.30M |
| Net income | -26.48M | -45.83M | -49.39M | -29.31M |
| Selling general administrative | 13.25M | 16.14M | 30.58M | 25.29M |
| Gross profit | -1.43M | -4.66M | 1.63M | 6.64M |
| Reconciled depreciation | 1.48M | 1.44M | 3.61M | 2.94M |
| Ebit | -25.06M | -32.07M | -31.68M | -29.35M |
| Operating income | -25.06M | -32.07M | -37.23M | -29.03M |
| Interest expense | - | 0.01M | 0.16M | 0.12M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.01M |
| Interest income | 0.04M | - | - | 0.18M |
| Net interest income | 0.04M | -0.01M | -0.16M | 0.05M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.01M |
| Total revenue | 4.76M | 2.21M | 16.53M | 22.11M |
| Total operating expenses | 29.82M | 34.28M | 53.76M | 51.14M |
| Cost of revenue | 6.19M | 6.87M | 14.89M | 15.48M |
| Total other income expense net | -1.18M | -2.52M | -12.00M | -0.32M |
| Discontinued operations | -0.28M | -11.23M | -13.54M | -13.54M |
| Net income from continuing ops | -26.20M | -34.60M | -49.39M | -29.31M |
| Net income applicable to common shares | -26.48M | -45.83M | -49.39M | -27.51M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 10.93M | 38.30M | 30.87M | 47.84M |
| Intangible assets | - | - | 6.29M | 11.13M |
| Other current assets | 4.88M | 4.57M | 3.03M | 0.00M |
| Total liab | 11.74M | 12.42M | 27.37M | 11.80M |
| Total stockholder equity | -0.81M | 25.88M | 3.50M | 36.04M |
| Other current liab | 1.30M | 1.78M | 12.81M | 0.12M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -304.56M | -278.09M | -229.91M | -180.52M |
| Other liab | 0.19M | 0.85M | 5.86M | 3.95M |
| Good will | - | - | 0.87M | 7.64M |
| Other assets | 0.05M | 0.11M | 14.88M | 1.65M |
| Cash | 1.08M | 23.22M | 6.86M | 8.81M |
| Total current liabilities | 11.40M | 11.22M | 19.93M | 9.41M |
| Short long term debt | - | - | 4.37M | 2.15M |
| Property plant equipment | 1.61M | 2.99M | 3.47M | 13.54M |
| Total current assets | 9.27M | 35.20M | 12.52M | 13.88M |
| Net tangible assets | -0.81M | 25.88M | 3.50M | 14.23M |
| Net receivables | 1.09M | 5.90M | 0.24M | 1.88M |
| Long term debt | - | - | 0.89M | - |
| Inventory | 1.24M | 0.42M | 1.23M | 2.06M |
| Accounts payable | 7.94M | 3.75M | 1.78M | 4.27M |
| Non currrent assets other | 0.05M | 0.11M | 0.05M | 1.60M |
| Non current assets total | 1.66M | 3.09M | 18.34M | 33.96M |
| Capital lease obligations | 0.34M | 0.69M | 1.60M | 1.93M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 3.48M | 0.28M | -0.95M | -2.87M |
| Change to liabilities | 3.29M | 1.81M | -0.34M | 0.48M |
| Total cashflows from investing activities | 3.48M | 0.28M | -0.95M | -2.87M |
| Net borrowings | - | 1.77M | 3.19M | -0.50M |
| Total cash from financing activities | 0.28M | 53.94M | 19.89M | 12.29M |
| Change to operating activities | -3.57M | -11.80M | 8.76M | -0.37M |
| Net income | -26.48M | -45.83M | -49.39M | -27.51M |
| Change in cash | -22.14M | 16.50M | -1.67M | -10.46M |
| Begin period cash flow | 23.25M | 6.75M | 8.81M | 19.27M |
| End period cash flow | 1.11M | 23.25M | 6.86M | 8.81M |
| Total cash from operating activities | -25.91M | -37.72M | -20.62M | -19.89M |
| Issuance of capital stock | 0.30M | 51.75M | 18.23M | 12.79M |
| Depreciation | 1.48M | 1.44M | 2.33M | 2.74M |
| Other cashflows from investing activities | 0.07M | 0.10M | -0.25M | -0.25M |
| Change to inventory | -0.82M | -0.24M | -1.77M | 0.02M |
| Change to account receivables | -0.24M | -0.57M | 0.32M | -0.75M |
| Other cashflows from financing activities | -0.01M | -5.43M | -1.53M | -1.01M |
| Change to netincome | 0.43M | 17.47M | 19.47M | 5.30M |
| Capital expenditures | 0.68M | 1.22M | 0.45M | 2.87M |
| Change in working capital | -1.34M | -10.80M | 5.13M | -0.62M |
| Stock based compensation | -0.34M | 1.98M | 4.42M | 5.87M |
| Other non cash items | 1.26M | 6.21M | 0.84M | 0.02M |
| Free cash flow | -26.58M | -39.01M | -21.85M | -22.75M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
11682 El Camino Real, San Diego, CA, United States, 92130
858 997 2400
11
| Name | Title | Year Born |
|---|---|---|
| Mr. Seth Abraham Cohen | Chief Financial Officer | 1963 |
| Mr. John W. Dorbin Jr. | General Counsel Corporate Secretary | 1971 |
| Mr. Eddie Wabern Glover | Chief Executive Officer of US Compounding Inc | 1950 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.